BP000493-PRO-558: Human Haptoglobin (HP) Protein
Source: Pooled human plasma-derived.
Purity: > 98% by RP-HPLC and SDS-PAGE.BP000493-PRO-567: Recombinant Human Haptoglobin (HP) Protein
Source: E. coli-derived.
Applications: Positive control for Western blot ; Antibody production; Protein assay.
Purity: > 90.0% by SDS-PAGE and HPLC.BP4200: Recombinant Dr. Nuclease
Source: E. coli-derived.
Specific activity: ≥1.1 x 10^6 U/mg. One unit of Dr. Nuclease is defined as the amount of enzyme required to produce a change in absorbance at 260 nm of 1.0 in the time of 30 minutes, under optimum conditions with excess substrate.
Purity: ≥95% by SDS-PAGE and ≥99% by SEC-HPLC. It does not contain any antimicrobial preservatives or protein stabilizers except glycerol (of synthetic origin).BP4200-GMP: Recombinant Dr. Nuclease, GMP Grade
Source: E. coli-derived.
Predicted molecular mass: ~28 kDa.
Specific activity: ≥1.1 x 10^6 U/mg. One unit of Dr. Nuclease is defined as the amount of enzyme required to produce a change in absorbance at 260 nm of 1.0 in the time of 30 minutes, under optimum conditions with excess substrate.
Purity: ≥95% by SDS-PAGE and ≥99% by SEC-HPLC. It does not contain any antimicrobial preservatives or protein stabilizers except glycerol (of synthetic origin).
Formulation: 0.2 μM filtered solution (250 units/ul) of 20 mM Tris-HCl, pH 8.0, 2 mM MgCl2, 2 mM NaCl, 50% Glycerol.
Endotoxin level: ≤0.01 EU/1000 units following 2020 ChP 1143 USP <85>.
Protease activity: No detectable protease activity using casein as substrate.
Residual host cell protein: ≤10.0 ppm by ELISA.
Mycoplasma: negative by qPCR method.
Bioburden: negative following 2020 ChP 1105 USP <61>.
Residual heavy metal: ≤10.0 ppm following 2020 ChP 0821 USP <32>.